By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intercell AG 

Campus Vienna Biocenter 6

Vienna    1030  Austria
Phone: 43-120620-0 Fax: 43-1-20620-800



Merck & Co.  Bacterial vaccines

Company News
Vivalis to Buy Intercell AG in European Biotech Merger for $174 Million 12/17/2012 7:58:56 AM
Intercell AG in Exploratory Talks With Private Equity, CEO Says 9/27/2011 8:12:47 AM
Novartis AG Has No Need to Buy Intercell AG, According to Source 7/19/2011 8:14:16 AM
Merck & Co., Inc. (MRK) and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 6/8/2011 6:26:41 AM
Intercell AG Announces Q1 2011 Results and Updates on R&D Progress 5/10/2011 9:41:18 AM
Intercell AG Taps COO Lingelbach as New CEO 5/5/2011 8:07:11 AM
Intercell AG, Merck & Co., Inc. (MRK) Told to Enroll No More Patients in Vaccine Clinical Test 4/11/2011 7:27:53 AM
Intercell AG Announces Next Steps of Development for Pseudomonas Vaccine 4/1/2011 7:09:58 AM
Intercell AG Announces Q4 and Preliminary Full Year 2010 Financial Results 3/1/2011 8:48:04 AM
Intercell AG Completes Placement of EUR 33.0 Million Senior Convertible Debt Financing 2/23/2011 6:23:53 AM